Each year, thousands of new disease biomarkers are published, but very few of them are able to reach the clinic and have meaningful impact on actual patient management. In this talk I will describe the lengthy and highly regulated process a biomarker or biomarker panel has to go through to have a chance to be accepted into clinical practice.
About the speaker
Erwin holds a PhD in molecular biology from the University if Ghent (Laboratory of Molecular Biology, Prof. Dr. Ir Walter Fiers, 1990) and an Executive MBA from Vlerick Business School (2009). Following his PhD, he moved to industry, holding a number of senior R&D management and business development positions in various Biotech companies in Belgium, such as Innogenetics, Ablynx and Biocartis. After a career of more than 30 years in the private sector, Erwin joined VIB in 2021 as the head of business development, with responsibility for technology transfer and industrial collaborations for the different VIB centres. Next to this, Erwin also leads a team of VIB scientists working on biomarker related translational projects at VIB Discovery Sciences.
Erwin is author and co-author of more than 100 publications published in peer-reviewed journals and is a (co-)inventor on 27 patents and patent applications.
